Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
OTLK.US
id: 864
Outlook Therapeutics (OTLK) Eye Treatment Case
D. New Jersey
Court2:23-cv-21862
Case number12/29/2022
Class period Start08/29/2023
Class period End01/02/2024
Lead Plaintiff motion deadline- Outlook announced promising results for ONS-5010, suggesting FDA approval was near. However, they faced FDA setbacks and withdrew their application.
- On August 30, 2023, the truth came out, leading to a 80% $OTLK fall.
Outlook Therapeutics announced positive data for ONS-5010 (its main product for wet AMD and retina diseases) in August 2021, suggesting it was ready for FDA approval, but then they withdrew and resubmitted their application due to FDA requests.
The lawsuit claims that throughout this time, Outlook provided false information about ONS-5010's effectiveness and manufacturing issues.
As a result, the FDA recently rejected their application, causing $OTLK fall by 80% and $297M loss of market cap, damaging shareholders.
Given all the information, investors have reasons to suspect that Outlook's eye treatment faced manufacturing and FDA approval issues that weren't properly disclosed.
Case Status
Motion to dismiss
Alleged Offence
Mismanagement,
Misleading Statements,
Omissions
Suspected Party
Directors,
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
08/30/2023
Filing date
11/03/2023
Lead Plaintiff Deadline
01/02/2024